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ABSTRACT
Background & Hypothesis
It has become clear that ALDH1 genes are involved in the pathobiology of various human cancers.
Several lines of evidence indicated that ALDH1 gene expression in tumors may be associated with
clinical prognosis outcomes. This hypothesis of our study is that ALDH1 genes may be used to predict
human cancer prognosis. In order to test this hypothesis, a systematic review of published articles, a
meta-analysis using Random-Effects model was conducted to assess the association between ALDH1
genes and clinicopathological features as well as survival outcomes.

Methods
Using PubMed, EMBASE and Web of Science, this study identified original English researches targeted
for association between ALDH1 genes and cancer prognosis for more than 20 patients during survival
analysis follow-up. This meta-analysis included original studies that evaluated a major clinical
outcomes (overall survival, disease progression, recurrence, and metastasis) in agnostic format for a
variety of cancer types and ALDH1 genes. Association of ALDH1 expression and clinicopathological
outcomes were evaluated using the Review Manager 5.3 software.

Results
One hundred and twenty one original researches were eligible for inclusion in this meta-analysis.
ALDH1 expression was significantly associated with poor overall survival of breast cancer, colon cancer,
non-small cell lung cancer, and ovarian cancer. ALDH1 expression was also associated with poor
prognosis of disease-free survival of breast cancer, non-small cell lung cancer, and rectal cancer. This
meta-analysis showed no association of ALDH1 expression with prognosis of esophageal squamous
carcinoma and Head and Neck Squamous Cell Carcinoma (HNSCC).

Conclusion
Expression of ALDH1 genes is associated with poor prognosis of breast cancer, colon cancer, non-small
cell lung cancer, ovarian cancer and rectal cancer.
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Background and Rationale
The human aldehyde dehydrogenase (ALDH) gene superfamily comprises nineteen genes that are
classified into eleven families and four subfamilies family. The ALDH genes encode proteins (isozymes)
that are catalytically-active, although some ALDH proteins appear to be catalytically-inactive. The
ALDH gene family also play an important physiological role in encoding proteins, leading to the
formation of either catalytically-active or catalytically-inactive proteins [1]. ALDH isoenzymes
participate in numerous biological processes mainly by catalyzing the oxidation of a wide spectrum of
aldehyde to carboxylic acids [2]. Aldehydes are highly reactive molecules that are generated during the
metabolism of either endogenous (e.g., amino acids, neurotransmitters, and carbohydrates) or
exogenous (cigarette smoke, food) agents [3]. The ALDH proteins ubiquitously exist in nearly all
subcellular tissues [4], with the majority of the ALDHs broadly distributed in tissues and hence display
distinct substrate specificity [5].

Historically the ALDH1 and ALDH2 genes are the most commonly studied enzymes that are responsible
for aldehyde oxidation and the enzymes have the highest concentration in the liver [6]. The significance
of ALDHs in physiological processes is based on compelling evidence that mutations and genetic
polymorphisms in ALDH genes are associated with phenotypes that extensively exist in humans and
rodents [7], such as alcohol-related diseases [8], cancer [9] and other neuro and endocrine diseases [10,
11]. In addition to the association between mutations in ALDH genes and clinical phenotypes, studies
with transgenic knockout mice further support the notion that ALDHs are crucial in less-studied
physiological functions such as embryogenesis and development [12].

The ALDH1 family is consists of six enzymes including ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1,
ALDH1L1 and ALDH1L2. ALDH1 genes catalyzes the detoxification of endogenous as well as
exogenous aldehydes, oxidization of retinol to synthesize retinoic acid [13]. ALDH1 is responsible for
the oxidation of intracellular aldehydes [14], contributing to the oxidation of retinol to retinoic acid in
stem cell differentiation process and has been widely identified as a novel tumor stem-like cell marker
in malignancies. ALDH1 is highly expressed in many stem and progenitor cells in several tissue types,
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which is believed to play a role in cancer [15]. As stem cells can asymmetrically divide into stem cell
or progenitor cell, and cancer is often regarded as uncontrolled proliferation of such stem cell [16].
Hence ALDH1 may be a biomarker of stemness. To date, ALDH1 activity has been used as a stem cell
marker for head and neck squamous cell carcinoma [17], lung cancer [18], prostate cancer [19],
pancreas cancer [20] and breast cancer [21]. ALDH1-positive cells can generate tumors from
xenotransplantation situation, thus ALDH1 might be used to describe the long-time-sought cancer stem
cells and even cancer prognosis [22]. According to Ginestier [23], the expression of ALDH1 in tumor
cells can disclose an earlier phase of progenitor cells. In addition, ALDH1-positive tumor cells may
have inherited aggressive properties including ability to self-renew, high proliferation potential, and
resistance to damaging agents. ALDH1 expression is associated with self-renewal of normal cells and
can be a predictor of poor prognosis among cancer patients [24]. The molecular level of ALDH1
researches can be transferred to practical utility of ALDH1 in clinical diagnosis and prognosis.

The primary function of ALDH1A1 concerns with encoding a homotetramer, which are ubiquitously
distributed in epithelium of various organs such as testis, brain, eye lens, liver, kidney, lung and retina
[25]. Recent studies suggest that ALDH1A1 may play an important role in cancer therapeutics prognosis
effect and mechanism [26], which may result from a decrease in effectiveness of anticancer drugs.
Because ALDH1A1 can detoxify major active aldehyde metabolites especially in breast cancer,
ALDH1A1 expression in the breast is associated with unfavorable clinical outcomes [21]. So breast
cancer patients who expressed lower ALDH1A1 expression status were likely to respond to CP-based
treatment significantly more compared to those who have higher ALDH1A1 expression level. Previous
studies also indicated that ALDH1A1 may be a predictor of the drug’s therapeutic effectiveness among
non-small cell lung cancer patients [27]. ALDH1A1 is not only a potential marker of cancer stem cells,
but also involves in the formation of tumor-initiating cells in ovarian tissues [28]. Besides this, a variety
of non-cancerous cells including hematopoietic progenitor cells can express higher ALDH1A1 levels
[4]. Original researches also indicated ALDH1 positive status is associated with epithelial-mesenchymal
transition, the process of which is considered to be prerogative in tumor metastases [29]. ALDH1A1
positive cells are enriched in CSCs and are associated with progression of bladder cancer [30]. Also the
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ALDH1A1 positive cells define invasive CSCs and ALDH1A1 predicts poor prognosis in esophageal
squamous cell carcinoma [31]. ALDH1A1 can downregulate certain cancers and has also been shown
to interact with certain anticancer drugs including daunorubicin and flavopiridol [32].

Like ALDH1A1, the isoenzyme of ALDH1A2 also has the function of encoding a cytosolic
homotetramer, which are expressed and exist in various embryonic tissues [33]. ALDH1A2 plays a
crucial role in regulating RA synthesis, therefore ALDH1A2 may affect cell growth and differentiation
as well as apoptosis, leading to an anticancer effect [4]. Previous studies indicated ALDH1A2 is a
candidate tumor suppressor for prostate cancer [34]. ALDH1A2 may be an excellent potential target for
individualized treatment for gastric cancer patients because ALDH1A2 demonstrates the association
with prognosis [35]. Other studies also suggest the implication of ALDH1A2 in for non-small cell lung
cancer [36]. Low ALDH1A2 expression is associated with unfavorable recurrence-free survival in nonsmall cell lung cancer patients [37].

Expression of ALDH1A3 has been found in a variety of organs such as salivary gland [38], stomach
[39], breast [40], kidney [41] and fetal nasal mucosa [42]. ALDH1A3 has been shown to play a critical
role in development of human tissues. Several studies have demonstrated that ALDH1A3 deficiency
may be correlated with prognosis of certain cancer types. Like ALDH1A1 and ALDH1A2, ALDH1A3
is also a cytosolic homodimer and participates in the synthesis of RA and even embryonic development
[43]. ALDH1A3 can be expressed in various late-stage embryonic and adult rodent tissues. Negative
ALDH1A3 expression in mouse embryos is leading such mice more likely to die from defects in nasal
development [44]. Previous studied reported that low ALDH1A3 expression status may play a critical
role in a variety of cancers [4]. ALDH1A3 expression has been found to be downregulated in human
breast cancer MCF-7 cells [45] and upregulated by induction of wild type p53 in cultured human colon
cancer cells [46]. ALDH1A3 has been proposed as a prognostic marker for nonmuscle invasive bladder
cancer [47]. ALDH1A3 expression is methylation-silenced in gastric cancer cells [48] and can be
induced by the antitumor agent IL-13 cytotoxin in glioblastoma cells [49], which results in different
prognosis outcomes in those tumor cells. ALDH1A3 belongs to the five candidate genes(Aldh1a3, Chd2,
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Nipa2, Pcsk6, and Tubgcp5) within a region related to mammary tumorigenesis [50]. In humans,
ALDH1A3 expression may be associated with enhancing malignant behavior of certain cancer types,
and ALDH1A3 might be a new therapeutic target for cancer treatment [51].

ALDH1B1 is a mitochondrial protein expressed and exist extensively in various human tissues including
liver, testis, kidney, skeletal muscle, heart, placenta, brain and lung [52]. Recent studies have shown
that ALDH1B1 is involved in the metabolism of the ethanol-derived acetaldehyde and may represent a
link between alcohol consumption and diabetes [53]. ALDH1B1 might be a crucial isozyme for colon
cancer tumorigenesis, because ALDH1B1 can modulate related signal pathways [53]. ALDH1B1
displays relatively high affinity for acetaldehyde and is believed to play a major role in acetaldehyde
oxidation in vivo [54].

The primary function of ALDH1L1 concerns with catalyzing the formation of tetrahydrofolate from 10formyltetrahydrofolate [55]. ALDH1L1 also has the function of cellular proliferation, so ALDH1L1
might be closely associated with cancer formation and progression. The positive expression of
ALDH1L1 in different cancer cell can result in suppressed cellular proliferation and increased
cytotoxicity, which might be attributed to its catalytic function[56]. ALDH1L1 is significantly
downregulated in human liver, lung, prostate, pancreas and ovarian cancers, which may enhance tumor
proliferation [57]. There consists with two intronic SNPs in ALDH1L1 and they are associated with one
increasing and one decreasing risk respectively for breast cancer patients, indicating potential influence
on breast cancer [58]. What’s more, ALDH1L1 is reported to have protective role for retinal cells [59].
Lower retinal tetrahydrofolate levels can affect ALDH1L1 in formate oxidation because of its additional
role of methanol toxicity [4]. ALDH1L1 may work as a good target for personal treatment among gastric
cancer patients, and ALDH1L1 may be associated with better overall survival in breast cancer patients
[38]. ALDH1L2 is one of the most recently found isoenzyme in ALDH superfamily and is mainly
expressed in spleen and corpus callosum tissue [60]. According to limited researches found, breast
cancer treatment that uses anti-inflammatory agent can upregulate ALDH1L2 expression [61].
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The total studies above indicate that enhanced ALDH1 expression might be a hallmark for cancer stem
cells(CSC) [62] and cancer stem cells are believed to possess characteristics of tumorigenesis in
particular cancer types [16]. The objective of this study was to systematically investigate the
significance of ALDH1 genes for prognosis and clinical outcomes in cancer patients. Hazard Ratio can
represent instantaneous risk over the follow-up time period and can indicate risks for the cumulative
follow-up period [63]. The survival analysis involves a series of follow-up time intervals between a
fixed starting point and the terminating event and in this study it’s the death of cancer patient [64]. The
calculation of Hazard Ratio differs from Relative Risk or Odds Ratio in case-control studies is that the
time contribution of individual cancer patients vary by the time of termination and their full survival
times remain unknown. The Kaplan-Meier survival curve and log-rank test to investigate difference
between two groups are examples of univariate analysis method, in which survival is described with
respect to the factor while ignoring other variables’ influence [65] . It’s more common in clinical
researches that more than one covariates or variables will exert influence on cancer patients’ prognosis,
including different genotypes, drug treatment, age, race or combination of these covariates. Therefore,
it’s more desirable to adjust these covariates while investigating the cancer patients’ survival in relation
to ALDH1 status. In previous survival analysis of cancer patients with ALDH, Hazard Ratio is the
comparison of death or recurrence corresponding to survival in patients between ALDH-positive and
ALDH-negative groups. The Cox Regression model [66] seeks to describe association between the
event incidence by hazard function and a set of covariates and the hazard is the instantaneous event
probability at a given time or the probability that an individual cancer patient under follow-up time
period the event in a time interval centered around that point.

In meta-analysis, the clinical outcomes for time-to-event survival analysis is Hazard Ratio for overall
survival or disease-free survival. However, not all studies include individual patient data and carry out
the Cox regression analysis for Hazard Ratio. Methods are still available to obtain HRs associated
statistics by carefully manipulating the published data that only include Hazard Ratio or Kaplan-Meier
curve[67]. It may be possible to extract data from published Kaplan-Meier curves by digitizing data
from a number of time intervals on the curves and then pool across these time intervals within a trial to
6

estimate HR that can represent the entire curve. The practical method proposed by Tierney[67] for
incorporating summary hazard ratio into meta-analysis can provide stronger analysis because excluding
researches that didn’t calculate HR may introduce a bias and may not report the necessary statistical
information to allow estimation of entire HRs. More often, the researches can present the outcomes in
different ways and by different cut-off point standard.

This study helps fill the gap of the efficacy and time-to-event association between candidate ALDH
genes with various cancer types. This study provides a more comprehensive review for ALDH1 genes
and cancer types, the result of which shed interesting light on whether ALDH1 is a good biomarker for
cancer patient prognosis. The association of ALDH1 and clinicopathological features of cancer patients
with corresponding prognostic outcomes remain controversial. The clinical significance of this metaanalysis study is the implementation ALDH1 in clinical prognosis prediction broadens the research area
of the already studied enzyme and pushes forward clinical utility in improving quality of cancer patients.
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Methods
The articles for this meta-analysis study is identified by searching the PubMed, EMBASE and Web of
Science databases. We searched English language studies that analyzed the associations between
ALDH1 genes expression and prognosis in cancer patients. The search strategy used the clinical queries
prognosis filter in databases mentioned above. And the key words for searching are as following:
(Prognosis/Broad[filter])AND(ALDH1 OR ALDH1A1 OR ALDH1A2 OR ALDH1A3 OR ALDH1B1
OR ALDH1L1 OR ALDH1L2)AND(cancer OR tumor OR neoplas* OR malignan* OR metastat* OR
recurrence) AND(Humans[Mesh] AND English[lang]).

The search results were then screened according to the following inclusion criteria:
1) evaluation of the association between ALDH1 genes expression and overall survival(OS) or diseasefree survival(DFS) or other prognostic factors among all types of cancer patients;
2) inclusion of validated data to calculate hazard ratio(HR) with a 95% confidence interval(95%CI) for
Overall Survival, Disease-Free Survival, or other prognostic outcomes among cancer patients;
3) inclusion of Kaplan-Meier survival curve to carry out data extraction and calculate unadjusted hazard
ratio(HR) based on follow-up information;
4) English language original researches;
5) inclusion of original researches with sufficient sample size of more than twenty patients;
6) articles published as original researches. Reviews were excluded.

The following five criteria were implemented to assess the quality of the original researches:
1) appropriate research design for survival analysis in cancer patients;
2) meeting the inclusion criteria stated in the previous paragraph;
3) clear research objectives for ALDH1 genes prognosis for different types of cancers;
4) appropriate statistical analysis for Hazard Ratio of clinical outcomes in prognosis prediction,
5) consideration of research bias and standardization.
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The following information was extracted from each published researches: title, first author, publication
year, key words, number of patients, histopathological cancer type, analysis method applied, cutoff
value of ALDH1 expression, Hazard Ratio, 95%CI for HR, p-value, Kaplan-Meier curve. The original
researches for screening and reviewing were before February 29, 2016.

Definitions and Standardizations
This study used a priori defined standardized outcomes and definitions for ALDH1 status to avoid
subjective selection of outcomes and definitions across studies as much as possible. Expression of
ALDH1 is measured by immunohistochemistry as part of the large gene analysis. For
immunohistochemistry, we define ALDH1-positive status as nuclear staining in tumor cells or at least
moderate staining in qualitative scales. The cut-off point may vary across included publications. If
different ALDH1-positive status were used, the cut-off point is recorded according the original papers.
The comparison groups for Hazard Ratio or Relative Risk in the survival analysis were transformed and
standardized to ALDH1-positive group vs. ALDH1-negative group, with negative expression as the
reference. The main outcome was Hazard Ratio for Overall Survival or Disease-Free Survival by Cox
Regression Analysis. To avoid bias that may arise, if investigators select the follow-up period to report
according to the results at each follow-up interval, we standardized definitions to include 24 months of
follow-up in all studies. Cox models that allow estimation of a hazard ratio for the entire follow-up
survival analysis are not routinely presented in ALDH1 studies.

Data Extraction
For each individual research, we recorded author name, journal and year of publication, sample size,
cancer type, demographics, gene and ALDH1 status for immunohistochemistry analyses, definition of
a ALDH1- positive status, cox model analysis used, outcome, HR, 95%CI, p-value during the analysis,
overall survival, disease-free survival. For papers didn’t include Hazard Ratio, we used Kaplan-Meier
survival curve and methods based on Tierney to calculate the Hazard Ratio for the study. The
PlotDigitizer was used to extract the data from Kaplan-Meier curve. According to Tierney[67], the
Hazard Ratio can be calculated in each time interval and two groups. The data taken into calculation
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include following steps:1) event-free at the start of the interval, 2) censored during the interval, 3) at
risk during the interval, 4) the number of events during each time interval, 5) O-E, V and HR for each
time interval, 6) O-E, V and HR for the entire Kaplan-Meier curve. PlotDigitizer can extract data for
numbers event-free at the start of specific time interval for ALDH1-positive group and ALDH1-negative
group. Overall HR and 95%CI can be calculated by the Calculations Spreadsheet provided by Tierney
[67].

Statistical Analysis
To determine poor clinical outcome associated with each category of ALDH1 genes and cancer types,
hazard ratio (HR) from time-to-event analyses was extracted along with the 95% confidence interval as
well as ALDH1 expression level. When the 95% confidence interval was not available from original
papers, two methods were used to validate the data of such studies. 95%CI can be calculated by HR and
p-value, or 95%CI can be approximated from Kaplan-Meier curve. The association of the expression
of ALDH1 and the general prognostic markers is assessed for breast cancer, colon cancer, esophageal
squamous cell, head and neck squamous carcinoma, non-small cell lung cancer, ovarian cancer and
rectal cancer, and the survival outcomes including overall survival, disease-free survival or other
prognosis outcomes. The published data and figures from original papers were used to assess the HR
according to the methods described by Parmar et al[68]. Adjusted Hazard Ratio was calculated by
multivariate analysis based on Cox Regression Model, and unadjusted Hazard Ratio was calculated by
univariate analysis. The Hazard Ratio calculated from Kaplan-Meier curve was unadjusted Hazard
Ratio. Both adjusted and unadjusted Hazard Ratio were included in this meta-analysis and were
categorized into different subgroups. The original research articles that meet the inclusion criteria of
this meta-analysis should be included, even if unadjusted Hazard Ratio for such articles needs to be
calculated from Kaplan-Meier curve. To exclude such articles may introduce bias for this meta-analysis.
Forest plots of Hazard Ratios of survival analysis were constructed to show the association between
ALDH1 gene expression and overall survival or disease-free survival, the outcomes of which were end
points in this meta-analysis. The p-values for Hazard Ratios were two-sided, with the significance cutoff point setting at smaller than 0.05.
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The heterogeneity assumption was calculated by using a Q-test, and P-values greater than 0.05 indicated
a lack of heterogeneity among studies. Hence the differences for subgroup studies were due to chance
and fixed-effect model was used. Otherwise, a random-effect model (DerSimonian-Laird method) was
used. I2 was chosen as the indicator for subgroup heterogeneity study and the cutoff standard for
choosing fixed-effect model or random-effect model was based on whether I2>50% and whether p>0.05.
In addition, in order to see whether individual studies will influence on the pooled effect, a sensitivity
analysis was performed. The sensitivity analysis sequentially excluded each individual study in each
meta-analysis and examined whether the pooled HRs were significantly changed. Funnel plots and
Egger’s test were constructed to estimate the possible evidence for publication bias. The funnel plots
included each individual studies with each point positioning in different X-axis(Hazard Ratio of the
study) and Y-axis(standard error of LogHR). The expected findings of smaller studies will distribute
randomly centered around the pooled Hazard ratio. And in comparison, larger studies will show tighter
cluster around the pooled Hazard Ratio. If there’s publication bias, the funnel plots will show an
asymmetric distribution. If no significant publication bias exists, all the studies will show a symmetric
triangular funnel on funnel plots. All statistics are processed by Review Manager 5.3(The Nordic
Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark). Generic Inverse Variance
Method is applied in Review Manager to conduct Hazard Ratio meta-analysis.
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Results

Figure 1. Flow diagram showing the inclusion and exclusion of studies on ALDH1 genes and all possible cancer prognosis.

Figure 1 and Table 1 show the flow of inclusion and exclusion process of studies on ALDH1 genes and
all possible cancer patients’ prognosis. A total number of one hundred and twenty one papers met the
inclusion criteria for this meta-analysis after screening abstracts and reviewing original papers. Four
thousand three hundred and fifty four papers were identified from PubMed, EMBASE or Web of
Science database. After excluding duplicated papers, one thousand and twenty three papers were
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screened for abstract. Three hundred and seventy seven papers were excluded based on screening result,
because such studies were cellular mechanism study rather than patients survival analysis. Seven
hundred and forty five papers were fully read and five hundred and fifty six full-text papers were
excluded. The exclusion reasons include: thirteen papers were animal studies with no population data,
one hundred and eighty three papers were cancer stem cell studies, one hundred and ninety-six papers
lacked follow-up information and only reported gene expression of ALDH1 genes, forty-four papers
were reviews, and twenty one papers were published in other languages. Among the remaining one
hundred and eighty nine eligible papers for systematic review, sixty-eight papers were excluded from
meta-analysis. The reasons include same study cohorts across researches, insufficient sample size (<20),
inadequate data for Hazard Ratio calculation and only reported p-value, logically inconsistent Hazard
Ratio. In the end, a total number of one hundred and twenty one original researches were eligible for
this meta-analysis.

Table 1. Flow table showing number of inclusion and exclusion of this meta-analysis studies.
ALDH1

ALDH1A1

ALDH1A2

ALDH1A3

ALDH1B1

ALDH1L1

ALDH1L2

Total published paper
(PubMed, EMBase and Web
of Science)

3064

860

111

186

63

60

10

Remaining papers after
excluding duplicates

595

252

48

68

22

28

10

Remaining papers after
screening (abstract only)

396

241

33

46

10

19

0

Remaining papers after fulltext review

111

51

5

13

1

8

0

Number of unique papers
for each category (after
excluding the ones with
insufficient data)

68

40

5

10

1

4

0

Total number of unique
papers for the meta-analysis

121

Table 2.1 Eligible studies for ALDH1 on cancer prognosis (not specifying the ALDH1 family). First author, cancer type, patient size, cut-off
point for ALDH expression, analysis method and outcomes are recorded.
First author

Cancer type

Patient
Number

gene

Cut-off point for
ALDH expression

Analysis
method

Outcomes

Liu[25]

astrocytoma

76

ALDH1

0

adjusted

OS, DFS

Goudarzi[69]

astrocytoma

36

ALDH1

0

unadjusted

CS

Ito[70]

axillary lymph node metastases

47

ALDH1

0

adjusted

DFS

Xu[71]

bladder cancer

227

ALDH1

0

adjusted

OS, DFS

13

Mieog[72]

breast cancer

193

ALDH1

0

adjusted

OS, DFS

Mieog[72]

breast cancer

61

ALDH1

0

unadjusted

OS, DFS

Yasuyo[73]**

breast cancer

257

ALDH1

0

adjusted

OS, DFS

Yasuyo[73]**

breast cancer

106

ALDH1

0

adjusted

DFS

CharafeJauffret[74]

breast cancer

77

ALDH1

0

adjusted

MFS, SS

Sakakibara[75]

breast cancer

115

ALDH1

0

adjusted

OS

Tan[76]*

breast cancer

139

ALDH1

0

unadjusted

DFS

Zhong[77]

breast cancer

121

ALDH1

0

adjusted

DFS

Genestier[28]

breast cancer

577

ALDH1

0

adjusted

OS

Kang[78]*

breast cancer

390

ALDH1

0

unadjusted

OS, DFS

Bane[79]*

breast cancer

255

ALDH1

NA

unadjusted

OS

Ito[73]**

breast cancer

47

ALDH1

0

adjusted

DFS

Zheng[80]

breast cancer

65

ALDH1

0

adjusted

OS

Nogami[81]

breast cancer

40

ALDH1

0

unadjusted

DFS

Neumeister[82]

breast cancer

642

ALDH1

NA

adjusted

OS

Huang[83]

breast cancer

552

ALDH1

0

unadjusted

DFS

Zhou[84]

breast cancer

61

ALDH1

0

adjusted

OS

Yu[85]*

breast cancer

96

ALDH1

0

unadjusted

DFS

Morimoto[86]

breast cancer

203

ALDH1

0

adjusted

OS

Bednarz-Knoll[87]

breast cancer

330

ALDH1

0

adjusted

OS, DFS

Dong[88]

breast cancer

161

ALDH1

0

adjusted

OS, DFS

Kim[89]

breast cancer

227

ALDH1

0

unadjusted

OS

Brot[90]

breast cancer

140

ALDH1

0

adjusted

OS

Hashimoto[91]*

breast cancer

92

ALDH1

0

unadjusted

OS, DFS

Lee[92]

breast cancer

184

ALDH1

0

adjusted

DFS

Santilli[93]

breast cancer

110

ALDH1

NA

adjusted

MFS, SS

Pistelli[94]

breast cancer

81

ALDH1

0

unadjusted

OS

Yao[95]

cervical cancer

198

ALDH1

0

adjusted

CS

Xie[96]

cervical cancer

52

ALDH1

0

adjusted

OS, DFS

Hou[97]

cervical cancer

179

ALDH1

NA

adjusted

OS, DFS

GoossensBeumer[98]

colon cancer

232

ALDH1

NA

adjusted

OS, DFS, DSS

Zhou[99]*

colon cancer

60

ALDH1

20%

unadjusted

CS

O'Dwyer[100]

colon cancer

28

ALDH1

0

unadjusted

CS

Vogler[101]

colon cancer

60

ALDH1

0

adjusted

OS

Rahadiani[102]

endometrioid adenocarcinoma

98

ALDH1

0

adjusted

OS, DFS

14

Honing[102]

esophageal squamous cancer

94

ALDH1

NA

unadjusted

OS, DFS

Minato[103]**

esophageal squamous cancer

56

ALDH1

0

adjusted

DFS

Minato[103]**

esophageal squamous cancer

40

ALDH1

0

adjusted

DFS

Minato[103]**

esophageal squamous cancer

56

ALDH1

0

adjusted

DFS

Wang[104]

esophageal squamous cancer

79

ALDH1

0

adjusted

OS

Hwang[105]*

esophageal squamous cancer

41

ALDH1

0%

unadjusted

CS

Ji[106]

esophageal squamous cancer

138

ALDH1

NA

adjusted

OS

Ajani[107]

esophageal squamous cancer

167

ALDH1

0

unadjusted

OS, DFS

Kim[108]

Eyelid Sebaceous Gland
Carcinoma

50

ALDH1

NA

adjusted

MFS, SS

Suzuki[109]

liver cancer

49

ALDH1

NA

unadjusted

DFS

Morise[110]

lung cancer

105

ALDH1

0

adjusted

OS, DFS

Okudela[111]

lung cancer

177

ALDH1

85%

adjusted

DFS

Zenke[112]

lung cancer

52

ALDH1

NA

adjusted

DFS

Liu[113]

oral cancer

141

ALDH1

0

adjusted

OS

Ayub[114]

ovarian cancer

55

ALDH1

0

adjusted

OS, DFS

Liebscher[115]

ovarian cancer

112

ALDH1

0

adjusted

OS

Kuroda[116]*

ovarian cancer

123

ALDH1

0

unadjusted

DFS

Chen[117]

ovarian cancer

80

ALDH1

0

adjusted

OS

Mizuno[118]*

ovarian cancer

81

ALDH1

10%

adjusted

OS

Huang[119]

ovarian cancer

232

ALDH1

NA

adjusted

OS

Wang[120]

ovarian cancer

84

ALDH1

50%

adjusted

OS

Chang[121]*

ovarian cancer

442

ALDH1

20%

adjusted

OS

Avoranta[122]

rectal cancer

197

ALDH1

0

adjusted

DFS

Seung[123]

rectal cancer

51

ALDH1

NA

adjusted

OS, DFS

Deng[124]*

rectal cancer

64

ALDH1

21%

unadjusted

DFS

Yoon[125]

rectal cancer

145

ALDH1

0

adjusted

DFS, CSS

GoossensBeumer[101]**

rectum cancer

73

ALDH1

NA

adjusted

OS, DFS, DSS

Liu[126]

renal pelvis carcinoma

114

ALDH1

0

unadjusted

OS, DFS

Huang[127]

tongue squamous cell
carcinoma

66

ALDH1

>1

unadjusted

OS

Kitamura[128]

urinary cancer

226

ALDH1

0

adjusted

CSS

Wu[129]*
volvar squamous cancer
154
ALDH1
NA: not applicable
*: The Hazard Ratio of these articles were calculated from Kaplan-Meier curve.
**: These articles included more than one cohort of analysis.

0

unadjusted

DFS
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Table 2.2: Eligible studies for ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1 and ALDH1L1 on cancer prognosis. First author, cancer type,
patient size, cut-off point for ALDH expression, analysis method and outcomes are recorded.
Cut-off point for
Analysis
First author
Cancer type
Patient Number
Gene
ALDH expression
method
Outcomes
Su[30]*

bladder cancer

216

ALDH1A1

NA

unadjusted

OS

Khoury[130]

breast cancer

513

ALDH1A1

NA

adjusted

OS, DFS

Liu[131]

breast cancer

596

ALDH1A1

0

adjusted

OS, DFS

Wei[132]

breast cancer

92

ALDH1A1

NA

adjusted

OS, DFS

Ali[133]

breast cancer

2392

ALDH1A1

4

adjusted

OS

Wu[134]

breast cancer

3455

ALDH1A1

NA

unadjusted

OS

Zhong[134]

breast cancer

147

ALDH1A1

0

adjusted

DFS

Zhou[135]

breast cancer

119

ALDH1A1

10%

adjusted

OS

Sjöström[136]

breast cancer

426

ALDH1A1

10%

adjusted

DFS

Kahlert[137]

colon and rectal
cancer

996

ALDH1A1

NS

unadjusted

OS, DFS

Xu[138]

colon cancer

107

ALDH1A1

>1

adjusted

OS

Yang[31]*

esophageal
squamous
carcinoma

134

ALDH1A1

NA

unadjusted

OS

Li[139]

gastric cancer

216

ALDH1A1

0

adjusted

OS, DFS

Shen[35]

gastric canceer

876

ALDH1A1

0

unadjusted

OS

Adam[140]

glioblastoma

93

ALDH1A1

0

adjusted

OS

Xu[141]

glioma

237

ALDH1A1

5

adjusted

OS

Qian[142]

HNSCC

81

ALDH1A1

0

adjusted

DFS

Koukourakis[143]

HNSCC

74

ALDH1A1

5%

adjusted

DFS

Xu[144]*

HNSCC

96

ALDH1A1

1.3

unadjusted

OS, DFS

Leinung[145]*

HNSCC

48

ALDH1A1

0

unadjusted

OS

Martin[146]

larygeal cancer

84

ALDH1A1

0%

adjusted

DFS

Tanaka[147]

liver cancer

60

ALDH1A1

>1

adjusted

DFS

Jiang[148]

lung cancer

303

ALDH1A1

10%

unadjusted

OS

Li[149]

lung cancer

179

ALDH1A1

0

adjusted

OS

Sullivan[150]

lung cancer

282

ALDH1A1

NA

unadjusted

OS

Shimada[151]

lung cancer

103

ALDH1A1

5%

adjusted

OS

0

unadjusted

DFS

134
Dimou[152]**

lung cancer

296

ALDH1A1

0

unadjusted

DFS

You[36]**

lung cancer

1926

ALDH1A1

NA

unadjusted

OS

Alamgeer[153]

lung cancer

205

ALDH1A1

NA

adjusted

OS, DFS

Gao[154]

lung cancer

133

ALDH1A1

0

adjusted

OS

Kaminagakura[155]**

oral squamous cell
carcinoma

100

ALDH1A1

10%

unadjusted

DFS

Ishiguro[156]

ovarian cancer

90

ALDH1A1

NA

unadjusted

OS, DFS
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Chui[157]

ovarian cancer

558

ALDH1A1

0

unadjusted

OS

Kahlert[158]

pancreatic cancer

97

ALDH1A1

4

adjusted

OS

Xing[159]

papillary thyroid
carcinoma

247

ALDH1A1

NA

adjusted

DFS

Li[160]

prostate cancer

163

ALDH1A1

10%

adjusted

OS, CSS

Magnen[161]*

prostate cancer

85

ALDH1A1

NA

unadjusted

OS

Sung[162]*

pulmonary
adenocarcinoma

97

ALDH1A1

NA

unadjusted

OS, DFS

Wang[163]

renal cancer

95

ALDH1A1

NA

unadjusted

OS, DFS

Aguilera[164]*

Sporadic colorectal
cancer

699

ALDH1A1

0

unadjusted

OS

Wu[138]**

breast cancer

3455

ALDH1A2

NA

unadjusted

OS

Shen[35]

gastric canceer

876

ALDH1A2

0

unadjusted

OS

Seidensaal[165]

HNSCC

101

ALDH1A2

NA

adjusted

OS, DFS

You[38]**

non-small cell lung
cancer

1926

ALDH1A2

NA

unadjusted

OS

Kostareli[166]*

oropharyngeal
squamous cancer

115

ALDH1A2

NA

unadjusted

OS, DFS

Kim[47]*

bladder cancer

163

ALDH1A3

0%

adjusted

DFS

Marcato[167]

breast cancer

176

ALDH1A3

NA

adjusted

OS

Jiang[168]

breast cancer

144

ALDH1A3

0%

adjusted

OS

Liu[131]

breast cancer

596

ALDH1A3

0

adjusted

OS, DFS

Wu[138]

breast cancer

3455

ALDH1A3

NA

unadjusted

OS

Qiu[169]*

breast cancer

125

ALDH1A3

0

unadjusted

OS

Shen[37]

gastric canceer

876

ALDH1A3

0

unadjusted

OS

NA

unadjusted

OS

177
Chen[170]*

glioma

443

ALDH1A3

NA

unadjusted

OS

You[38]**

non-small cell lung
cancer

1926

ALDH1A3

NA

unadjusted

OS

0

adjusted

OS

46
Casanova-Salas[171]

prostate cancer

80

ALDH1A3

0

adjusted

OS

You[38]**

lung

1926

ALDH1B1

NA

unadjusted

OS

Wu[138]**

breast cancer

3455

ALDH1L1

NA

unadjusted

OS

Shen[37]**

gastric canceer

876

ALDH1L1

0

unadjusted

OS

Chen[172]

liver cancer

112

ALDH1L1

0

adjusted

OS

NA

unadjusted

OS

You[38]**
lung
1926
ALDH1L1
NA: not applicable
*: The Hazard Ratio of these articles were calculated from Kaplan-Meier curve.
**: These articles included more than one cohort of analysis.
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Table 2.1 listed the characteristics of eligible studies to examine association of ALDH1 genes and cancer
prognosis. Sixty eight papers were eligible and it covers nineteen different cancer types. This sixty eight
papers didn’t specify the ALDH1 genes. Through the inclusion flow process, we can find the majority
of original researches didn’t specify ALDH1 genes isozymes. This might be due to the limitation of
experiment design, the budget for identifying gene marker. Some paper incorporated ALDH1 as
ALDH1A1, perhaps ALDH1A1 was the main and largest gene type for ALDH1 genes. However, in this
meta-analysis, we separate the original researches of ALDH1 as a specific subgroup. Table 2.2 listed
the characteristics of eligible studies for ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, and
ADLH1L1. Forty papers were available for ALDH1A1 and prognosis studies and they covered eighteen
cancer types. Five papers examined prognosis effect of ALDH1A2 and five different cancers. Ten
papers targeted on ALDH1A3 and six cancer types were studied. Only one paper was available for
ALDH1B1. Four papers studied ALDH1L1 and four cancer types. Two papers [38, 139] categorized
ALDH1 genes into each specific subgroups, thus records were repeated for available study number and
patient number included.
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Figure 2.1 Association between ALDH1 genes and Overall Survival for breast cancer

Figure 2.1 shows the results of the meta-analysis of ALDH1, ALDH1A1, ALDH1A3 expression in
prognosis of overall survival in breast cancer patients, for which sixteen papers were available for
association with ALDH1, six papers were available for association with ALDH1A1 and five papers were
available for association with ALDH1A3. A total number of 11,983 breast cancer patients were
identified by three ALDH1 genes and were evaluated for overall survival as a clinical outcome. The
pooled hazard ratio for overall survival using Random Effect Model between ALDH1 genes positive
patients and ALDH1 genes negative patients is 1.83, with 95%CI of (1.46, 2.28), which suggested
ALDH1 genes were a significant poor prognosis predictor for overall survival in breast cancer

19

patients(p<0.001). ALDH1 genes show different prognosis effect when the HR is calculated by
multivariate analysis of Cox Regression model with controlling covariates and univariate analysis
without controlling covariates, because adjusted HRs are less biased. The Hazard Ratio for adjusted
Overall Survival is 2.52(95%CI: 1.77, 3.60) between breast cancer patients with ALDH1 positive
expression and breast cancer patients with ALDH1 negative expression (p<0.001). In comparison, the
Hazard Ratio for unadjusted Overall Survival falls to 0.98(95%CI: 0.57, 1.67) between the ALDH1
positive and negative caner patients. Similarly, the Hazard Ratio for adjusted Overall Survival is
2.65(95%CI: 0.98, 7.12) for breast cancer patients ALDH1A1 positive expression compared to patients
with negative expression. For ALDH1A3, the Hazard Ratio for multivariate Overall Survival is
1.75(95%CI: 1.02, 2.97) for breast cancer patients with positive expression versus patients with negative
expression. The Hazard Ratio falls to 1.09(95%CI: 0.97, 1.22) for univariate Overall Survival for breast
cancer patients with positive ALDH1A3 expression and negative ALDH1A3 expression. The I2 of
Heterogeneity analysis indicated the overall studies and subgroup studies have significant heterogeneity
for the association between ALDH1 genes and breast cancer overall survival (I2>50%, p<0.05), thus
random-effect model is applied for this meta-analysis. This forest plot indicated that Overall Survival
with adjusted HR of ALDH1 genes predicts a significant poor prognosis for breast cancer patients, while
Overall Survival with unadjusted HR may not be a significant prognosis predictor for breast cancer
patients. In sensitivity analysis, each study was sequentially excluded to examine if change in the pooled
Hazard Ratio was significant. No significant change was found for meta-analysis between ALDH1
genes and overall survival in breast cancer.
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Figure 2.2. Association between ALDH1 genes and Disease-Free Survival in Breast Cancer

Figure 2.3 Association between ALDH1 genes and Disease-Free Survival in Breast Cancer after sensitivity analysis.
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Figure 2.2 is the forest plot of indicating expression of ALDH1, ALDH1A1, ALDH1A3 in prognosis of
disease-free survival (DFS) in breast cancer patients, for which twenty papers were included for this
analysis. A total number of 4,073 breast cancer patients were identified by ALDH1, ALDH1A1 and
ALDH1A3 in subgroup analysis. The pooled Hazard Ratio for disease-free survival between breast
cancer patients with ALDH1 genes positive expression and patients with negative expression is 2.15
with 95%CI of (1.45, 3.18) and the poor prognosis for disease-free survival is significant (p<0.001).
For the ALDH1 genes subgroup, the hazard ratio for adjusted DFS is 2.00(1.24, 3.23) in breast cancer
patients with positive ALDH1 expression versus patients with negative expression. The hazard ratio for
DFS in breast cancer patients was 2.28(0.58, 8.94) when the multivariate analysis is switched to
univariate analysis. The adjusted HR for DFS is 2.02(0.86, 4.74) for breast cancer patients with positive
ALDH1A1 expression in comparison to patients with negative ALDH1A1 expression. Based on the
heterogeneity results, the subgroup for ALDH1 and unadjusted DFS in breast cancer patients showed
insignificant heterogeneity (I2<50, p=0.11). But the pooled HR analysis and other subgroups show
significant heterogeneity (I2>50, p<0.05). So random-effect model is used for meta-analysis between
ALDH1 genes and prognosis of disease-free survival in breast cancer patients. This forest plot indicated
that adjusted Disease-Free Survival of ALDH1 genes predicts a significant poor prognosis for breast
cancer patients, while unadjusted Disease-Free Survival may not be a significant prognosis predictor
for breast cancer patients. In Mieog’s study [69], patients were categorized into two groups based on
their age (.>65ys) and the disease-free survival were conducted respectively in these two cohorts. When
conducting sensitivity analysis for this meta-analysis, we found research by Charafe-Jauffret [71] for
association of ALDH1 and adjusted DFS among breast cancer patients exerted significant changes for
the pooled Hazard Ratio. This original research concluded by Kaplan Meier univariate analysis for
metastasis free survival of 74 inflammatory breast carcinomas, without controlling the covariates that
may contribute to disease-free survival. After deleting the result of this study, the pooled unadjusted
Hazard Ratio of disease-free survival related to ALDH1 genes among breast cancer patients falls to 1.28
(95%CI: 0.83, 1.96). The overall Hazard Ratio of disease-free survival is 1.61 (95%CI: 1.26, 2.06)
between breast cancer patients who expressed ALDH1 genes and who didn’t, as showed in Figure 2.3
after conducting sensitivity analysis.
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Figure 3. Association between ALDH1 genes and Overall Survival in Colon Cancer

Figure 3 is the forest plot to show the association of ALDH1 genes expression and prognosis of overall
survival in colon cancer patients. Six studies were included into this meta-analysis and a total number
of 2,135 colon cancer patients were followed up for overall survival analysis. The pooled Hazard Ratio
for Overall Survival in Colon Cancer between patients with positive expression of ALDH1 genes and
patients with negative expression of ALDH1 genes is 2.13(95%CI: 0.97, 4.66) and HR of OS is
significant predictor for poor prognosis. The adjusted Hazard Ratio of overall survival in colon cancer
patients with positive ALDH1 expression is 6.50(95%CI: 3.17, 13.33) in comparison to colon cancer
patients with negative ALDH1 expression. This Hazard Ratio calculated by Cox Regression Model is
significant (p<0.001). The unadjusted Hazard Ratio for Overall Survival in colon cancer patients with
positive ALDH1 gene is 0.78(95%CI: 0.29, 2.11) in comparison to patients with negative ALDH1
expression and this unadjusted HR is not significant (p=0.631). The adjusted Hazard Ratio for Overall
survival in colon cancer patients with positive ALDH1A1 expression is 2.11(95%CI: 1.32, 3.38) versus
patients with negative ALDH1A1 expression. And the unadjusted Hazard Ratio for Overall Survival
between positive ALDH1A1 expression patients and negative expression patients is 2.44(95%CI: 1.29,
4.61). For ALDH1A1 subgroups, only one paper was included specifically for each of the two subgroups.
The test for subgroup differences indicated the heterogeneity was significant among the papers in
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different subgroups (I2>50%, p=0.006). Random-effect model was conducted in this meta-analysis to
examine association between ALDH1 genes and Overall Survival in Colon Cancer. This forest plot
indicated that ALDH1 genes for adjusted Overall Survival among colon cancer patients predict a
significant poor prognosis, while ALDH1 genes may not be a significant prognosis predictor for colon
cancer patients with unadjusted Overall Survival. In the sensitivity analysis, the original researches from
Goossens-Beumer [95] and Zhou [96] would change the pooled Hazard Ratio significantly. But based
on the limited availability of researches on colon cancer prognosis, more investigation was required for
prognosis effect. The cut-off points in these two studies were 50% and 20% respectively, which means
after standardizing expression cut-off points, the hazard ratio can be larger than this estimation.

Figure 4.1 Association between ALDH1 genes and Overall Survival in Esophageal Squamous Carcinoma

Figure 4.2 Association between ALDH1 genes and Disease-Free Survival in Esophageal Squamous Carcinoma
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Figure 4.1 and Figure 4.2 are the forest plots that examine association between ALDH1 genes and
Overall Survival as well as Disease-Free Survival among patients with Esophageal Squamous
Carcinoma. Six papers were available for overall survival meta-analysis for esophageal squamous
carcinoma and a total number of 652 patients were followed up for overall survival. The pooled Hazard
Ratio of overall survival is 1.22 (95%CI: 0.82, 1.81) between esophageal squamous carcinoma patients
who had positive ALDH1 gene expression and who had negative ALDH1 gene expression. This poor
prognosis prediction of overall survival is not significant (p=0.33). The heterogeneity among papers for
overall survival analysis is significant (I2>50%, p=0.03), thus random-effect model was implemented
in this analysis. For subgroup differences test, the heterogeneity among papers that reported overall
survival using Cox Regression Model is not significant (I2<50%, p=0.61) and heterogeneity among
papers that reported univariate overall survival is significant(I2>50%, p=0.02). The pooled adjusted
Hazard Ratio of overall survival is 1.49 (95%CI: 1.07, 2.08) between esophageal squamous carcinoma
patients who had positive ALDH1 expression and who had negative ALDH1 expression. The poor
prognosis prediction of ALDH1 for adjusted overall survival is significant (p=0.02), however only two
papers were analyzed for this prognosis. The pooled unadjusted Hazard Ratio of overall survival is
1.14(95%CI: 0.61, 2.13) for esophageal squamous carcinoma between patients with positive ALDH1
and patients with negative ALDH1 expression. Four papers and 260 patients were included and the
association is not significant (p=0.74). Based on such findings, it’s ideal for original researches to carry
out multivariate analysis for adjusted Hazard Ratio to evaluate the association between ALDH1 genes
and prognosis for cancer patients. The sensitivity analysis didn’t find any individual research would
significantly alter the pooled Hazard Ratio.

Three papers and 412 esophageal squamous carcinoma patients were included for meta-analysis of
association of ALDH1 expression and disease-free survival prognosis. The heterogeneity is significant
in this meta-analysis (I2>50%, p<0.001) and significant for both subgroup analysis (p<0.001), thus
random-effect model was used for pooled Hazard Ratio analysis. The pooled Hazard Ratio for diseasefree survival including adjusted HR and unadjusted HR for esophageal squamous carcinoma is 1.84
(95%CI: 0.70, 4.84) between patients with positive ALDH1 expression and patients with negative
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ALDH1 expression. From the pooled HR, ALDH1 did not predict a significant poor prognosis for
recurrence of esophageal squamous carcinoma (p=0.64). The adjusted disease-free survival of
esophageal cancer patients included three different cohorts from one paper included surgery without
induction therapy group (OP), surgery with neoadjuvant chemotherapy group (NAC) and initial
systemic chemotherapy group (CT). In the OP and NAC groups, multivariate analysis found that
ALDH1 was independently associated with postoperative recurrence and prognosis (OP group, P =
0.004 and 0.016, respectively; NAC group, P = 0.026 and 0.014, respectively). Among the ALDH1negative clinical stage II/III patients, the OP and NAC groups displayed better prognoses than the CT
group (P<0.001). However, among the ALDH1-positive clinical stage II/III patients, the OP and NAC
groups displayed poorer prognoses than the CT group (P = 0.049). For the unadjusted disease-free
survival analysis, two papers indicated two different prognosis effect, a significant poor prognosis with
Hazard Ratio 3.87 (95%CI: 1.47, 10.16) and a significant good prognosis with Hazard Ratio 0.55
(95%CI: 0.34, 0.89). The patients who showed poor prognosis of disease-free survival with esophageal
squamous carcinoma underwent preoperative chemoradiation, so the different prognosis effects might
be due to the diversified treatment for patients. The treatment patients received can be an important
covariate that will influence the hazard ratio if not controlled by Cox Regression Model. Based on the
limited researches found for disease free survival of esophageal squamous carcinoma patients and
ALDH1 prognosis effect, the sensitivity analysis may not fit in this case.

Figure 5. Association between ALDH1 genes and Disease-Free Survival in Head and Neck Squamous Cell Carcinoma
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Five papers were included for meta-analysis of association between ALDH1 genes expression and
disease-free survival in Head and Neck Squamous Cell Carcinoma(HNSCC). A total number of 388
HNSCC patients were included in this association analysis. The pooled Hazard Ratio for disease-free
survival in HNSCC patients with positive ALDH1 genes expression is 1.04(95%CI: 0.55, 1.96) in
comparison to patients with negative expression. The Hazard Ratio for disease-free survival included
both adjusted HR and unadjusted HR [143]. The heterogeneity of the five papers is significant (I2>50%,
p=0.05), indicating more investigation should be conducted to examine the association of ALDH1 genes
expression and HNSCC prognosis.. The pooled HR didn’t show that ALDH1 genes are significant poor
prognosis of disease-free survival among HNSCC patients. This meta-analysis didn’t separate
univariate disease-free survival and multivariate disease-free survival as subgroups based on papers
identified. Based on the limited availability of researches found and the subgroups analysis, sensitivity
analysis was not conducted in this meta-analysis.

Figure6.1 Association between ALDH1 genes and Overall Survival in Non-Small Cell Lung Cancer

Figure 6.1 is the forest plot to show the association of ALDH1 genes expression and overall survival in
non-small cell lung cancer(NSCLC) patients. Seven papers were included into this meta-analysis and a
total number of 2995 NSCLC patients were followed up for overall survival. The pooled Hazard Ratio
for Overall Survival is 1.94 (95%CI: 1.23, 3.07) between NSCLC patients with positive ALDH1 genes

27

expression versus patients with negative ALDH1 genes expression, and the prediction for poor
prognosis is significant (p=0.004). The heterogeneity result indicated a significant heterogeneity for
subgroup differences (I2>50%, p<0.01), with the heterogeneity in subgroup of ALDH1A1 and adjusted
OS not significant (I2=0%, p=0.50), heterogeneity in subgroup of ALDH1A1 and unadjusted OS
significant (I2>50%, p<0.01). Random-effect model is conducted for this meta-analysis in ALDH1
genes and OS in NSCLC patients. The adjusted Hazard Ratio by multivariate analysis of overall survival
in NSCLC is 2.74 (95%CI: 2.03, 3.69) between patients with positive ALDH1A1 expression and patients
with negative ALDH1A1 expression (p<0.001). The unadjusted Hazard Ratio by univariate analysis of
overall survival in NSCLC is 1.18(95%CI: 1.23, 3.07) between patients with positive ALDH1A1
expression and patients with negative ALDH1A1 expression (p=0.45). The difference in prediction of
NSCLC overall survival can be attributed to other covariates that may contribute to this association.
Based on sensitivity analysis, no individual researches significantly altered the pooled Hazard Ratio.

Figure 6.2 Association between ALDH1 genes and Disease-Free Survival in Non-Small Cell Lung Cancer

Figure 6.2 is the forest plot to show the association of ALDH1 genes expression and disease-free
survival prognosis among NSCLC patients. Five papers were included in this meta-analysis and a total
of 937 patients were followed-up for disease-free survival analysis. This meta-analysis was categorized
into two subgroups, association of ALDH1 genes and adjusted Disease-free survival in NSCLC and
association of ALDH1A1 expression and adjusted DFS in NSCLC. The pooled Hazard Ratio of diseasefree survival is 1.32(95%CI: 0.65, 2.66) for NSCLC patients with positive ALDH1 genes expression in
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comparison to NSCLC patients with negative ALDH1 expression. This pooled Hazard Ratio is not
significant and the pooled Hazard Ratio between the two subgroups indicated different prognosis effects.
The Hazard Ratio for disease-free survival in NSCLC patients by Cox Regression Model is 2.50(95%CI:
1.51, 4.12) between patients who expressed ALDH1 and patients who didn’t express ALDH1. The
association is significant (p<0.001) and heterogeneity is not significant (p=0.81). The Hazard Ratio for
disease-free survival in NSCLC patients by Cox Regression Model is 0.75(95%CI: 0.28, 1.97) between
patients who expressed ALDH1A1 and patients who didn’t express ALDH1A1. This prognosis
association is insignificant (p=0.55) and heterogeneity is significant (p<0.001). Random-Effect model
is used to conduct this meta-analysis. The sensitivity analysis didn’t find significant change of
individual research on pooled Hazard Ratio. The original research by Dimou [151] included two cohort
of Yale cohort and Sotirial/Patras cohort, and followed-up the cohort separately and provided two
hazard ratio for disease-free survival for NSCLC. To sum up, ALDH1 might be a poor prognosis for
disease-free survival among patients suffering non-small cell lung cancer.

Figure 7. Association between ALDH1 genes and OS prognosis in ovarian cancer

Figure 7 is the forest plot to examine association between ALDH1 genes expression and overall survival
prognosis in ovarian cancer. Nine papers and a total of 1,257 ovarian cancer patients were included for
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this overall survival meta-analysis. Random-effect model was used because the heterogeneity is
significant for subgroups (p<0.05). The pooled Hazard Ratio for overall survival of ovarian cancer is
1.48 (95%CI: 1.12, 1.96) between patients who expressed ALDH1 genes and who didn’t ALDH1 genes
and the overall survival prognosis is significant (p<0.001). For patients who expressed ALDH1 genes
and who didn’t express, the hazard ratio for overall survival is 1.68 (95%CI: 1.02, 2.76) and the
association is significant (p=0.04). The unadjusted Hazard Ratios for overall survival of ovarian cancer
between patients who expressed ALDH1 and who didn’t, between patients who expressed ALDH1A1
and who didn’t are 1.85(95%CI: 0.94, 3.63) and 1.40(95%CI: 0.68, 2.86) and they are not significant
(p<0.05). The cut-off points in deciding positive and negative ALDH1 genes expression are not uniform,
with some original researches setting 0%, and some setting 10%, or 50%. The univariate analysis for
overall survival among ovarian cancer patients might be influenced by other factors. The sensitivity
analysis didn’t find a significant change in pooled Hazard Ratio of overall survival for ovarian cancer
when taking away each individual study.

Figure 8. Association between ALDH1 genes and prognosis in Rectal Cancer

Figure 8 is the forest plot to examine the association of ALDH1 genes and prognosis in rectal cancer
patients. Four papers were included in the meta-analysis and a total of 481 rectal cancer patients were
analyzed for disease-free survival prognosis. The heterogeneity of overall researches and subgroup
researches was not significant (p>0.05), so fixed-model model was used in this meta-analysis. The
papers we found for rectal cancer analysis only included ALDH1 genes expression, and the prognosis
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included overall survival and disease-free survival. The pooled Hazard Ratio of disease-free survival
for rectal cancer patients is 2.57 (95%CI: 1.15, 5.73) between patients who expressed ALDH1 genes
and who didn’t express it. This pooled Hazard Ratio for disease-free survival is significant (p=0.02). In
this meta-analysis, the unadjusted DFS hazard ratio was calculated from Kaplan-Meier curve. But in
the original paper, multivariate Cox analysis showed postoperative ALDH1 independently predicted
poor prognosis in patients with rectal cancer who received radiochemotherapy (P=0.0095). The pooled
disease-free survival of rectal cancer patients indicated that ALDH1 is a significant poor prognosis
predictor for disease-free survival. This result provides a potential prognosis research field for rectal
cancer, which hasn’t been investigated much by researchers. The sensitivity analysis didn’t find
significant change in pooled Hazard Ratio of disease free survival when sequentially excluding each
study from the meta-analysis.

Figure 9.1 Association between ALDH1A2 and prognosis in different cancers

Figure 9.1 is the forest plot to examine the association of ALDH1A2 expression status and overall
survival in cancer patients. Five papers specified ALDH1A2 expression in five different cancer types
including breast cancer, gastric cancer, head and neck squamous cell carcinoma, non-small cell lung
cancer and oropharyngeal squamous cancer and a total number of 5905 patients were analyzed for
overall survival. The heterogeneity is significant in this meta-analysis (I2>50%, p<0.001), and the
prognosis effect vary across the different cancer types. Four papers reported overall survival by
univariate analysis, and the pooled Hazard Ratio might be influenced by other covariates that were not
controlled in the analysis. The pooled Hazard Ratio of overall survival in cancer patients is 0.85 (95%CI:
0.60, 1.20) between patients with positive ALDH1A2 expression and negative ALDH1A2 expression
and the association is not significant (p=0.36).
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Figure 9.2 Association between ALDH1A3 and prognosis in different cancers

This forest plot examines the association between overall survival of different cancer patients and
ALDH1A3 expression. Ten papers analyzed ALDH1A3 expression association and were included in this
meta-analysis, with a total number of 8205 patients. The ten papers analyzed six types of cancers
including bladder cancer, breast cancer, gastric cancer, glioma, non-small cell lung cancer and prostate
cancer. The heterogeneity of the ten papers was significant (I2>50%, p<0.001) and random-effect model
was used to calculate the pooled Hazard Ratio. The pooled Hazard Ratio for overall survival of cancer
patients is 1.63 (95%CI: 1.02, 2.62) between patients with positive ALDH1A3 expression and patients
with negative ALDH1A3 expression. And the pooled Hazard Ratio is statistically significant (p<0.001).
Based on the availability of original researches found, subgroups analysis wasn’t conducted to examine
the prognosis effect for each cancer types. The pooled Hazard Ratio indicated a significant poor
prognosis effect in cancer patients who expressed ALDH1A3. Therefore, ALDH1A3 might be a potential
poor prognosis predictor for cancer patients.

Figure 9.3 Association between ALDH1L1 and prognosis in different cancers

This forest plot is an attempt to see if there’s association between ALDH1L1 expression and overall
survival in cancer patients including liver cancer, gastric cancer, breast cancer and non-small cell lung
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cancer. Four papers were included in this analysis with a total number of 6353 patients of four different
cancer types. The heterogeneity is significant among the four original researches (I2>50%, p<0.001),
and the different cancer types may lead to various overall survival. A better scrutiny of each Hazard
Ratio for overall survival, we can see the prediction of good prognosis or poor prognosis for different
cancer types vary. The pooled Hazard Ratio of overall survival between cancer patients with positive
ALDH1L1 expression and patients with negative ALDH1L1 expression is 1.00 (95%CI: 0.65, 1.54).
Even if the pooled HR didn’t show prognosis effect, more investigation is worthwhile to disclose the
association.

Table 3 Hazard Ratio for association between ALDH1 gene expression status and prognosis of cancers, specified by Random effect
model and Fixed effect model calculation

Levels of Synthesized Information

No. of Studies (No. of
Patients)

Random Effects Hazard
Ratio Estimates (95%CI)

Fixed Effects Hazard
Ratio Estimates (95%CI)

Overall Survival of Breast Cancer

25(11,983)

1.83(1.46, 2.28)

1.09(1.03, 1.16)

ALDH1 and adjusted OS in breast cancer

11(2,640)

2.52(1.77, 3.60)

1.84(1.61, 2.10)

ALDH1 and unadjusted OS in breast cancer

6(1,233)

0.98(0.57, 1.67)

1.09(0.82, 1.44)

ALDH1A1 and adjusted OS in breast cancer

5(4,210)

2.65(0.98, 7.12)

0.89(0.83, 0.97)

ALDH1A3 and adjusted OS in breast cancer

2(320)

1.75(1.02, 2.97)

1.70(1.09, 2.66)

ALDH1A3 and unadjusted OS in breast cancer

2(3,580)

1.09(0.97, 1.22)

1.09(0.97, 1.22)

Disease Free Survival of Breast Cancer

21(4,703)

2.15(1.45, 3.18)

1.06(0.99, 1.13)

ALDH1 and adjusted DFS in breast cancer

8(1,418)

2.00(1.24, 3.23)

1.01(0.90, 1.12)

ALDH1 and unadjusted DFS in breast cancer

8(1,517)

2.28(0.58, 8.94)

3.62(2.83, 4.61)

ALDH1A1 and adjusted DFS in breast cancer

5(1,768)

2.02(0.86, 4.74)

0.93(0.85, 1.01)

Overvall Survival of Colon Cancer

9(2,135)

2.13(0.97, 4.66)

1.64(1.26, 2.15)

Overall Survival of esophageal squamous carcinoma

6(652)

1.22(0.82, 1.81)

1.23(0.99, 1.54)

ALDH1 and adjusted OS in esophageal carcinoma

2(217)

1.49(1.07, 2.08)

1.49(1.07, 2.08)

ALDH1 and unadjusted OS in esophageal carcinoma

4(435)

1.14(0.61, 2.13)

1.05(0.78, 1.42)

Disease Free Survival of Esophageal Carcinoma

3(412)

1.84(0.70, 4.84)

0.90(0.66, 1.23)

Disease Free Survival of HNSCC

5(388)

1.04(0.55, 1.96)

1.12(0.83, 1.52)

Overall Survival of NSCLC

8(2995)

1.94(1.23, 3.07)

1.11(0.99, 1.23)

Disease Free Survival of NSCLC

5(937)

1.32(0.65, 2.66)

1.32(0.65, 2.66)

Overall Survival of Ovarian Cancer

9(1,257)

1.48(1.12, 1.96)

1.10(0.92, 1.32)

Disease Free Survival of Rectal Cancer

4(491)

2.57(1.15, 5.73)

2.57(1.15, 5.73)

33

Figure 10.1 Funnel plot of ALDH1 genes expression and breast cancer overall survival, as a means of assessing publication bias.
Figure 10.2 Funnel plot of ALDH1 genes expression and breast cancer disease-free survival

Figure 10.1 and Figure 10.2 are funnel plots to check the existence of publication bias for meta-analysis.
Y-axis, logHR, represents size of studies and X-axis represents the Hazard Ratio for each individual
study. The ideal situation of no publication bias will present large studies plotting near pooled Hazard
Ratio and small studies spreading randomly on both sides, which creates a funnel-shaped distribution.
Figure 10.1 indicated no obvious evidence of publication bias for association between ALDH1 and
overall survival in breast cancer. Figure 10.2 showed minor evidence of publication bias for association
between ALDH1 and disease-free survival in breast cancer as there was one outlier point in the funnel
plot. The findings suggested ALDH1 genes can be a strong prognosis marker for breast cancer patients.
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Figure 10.3 Funnel plot of ALDH1 genes expression and overall survival in colon cancer
Figure 10.4 Funnel plot of ALDH1 genes expression and overall survival in esophageal squamous carcinoma
Figure 10.5 Funnel plot of ALDH1 genes expression and disease-free survival in esophageal squamous carcinoma

No significant publication bias was found from the three studies, which suggested the pooled Hazard
Ratio of prognosis of ALDH1 genes can be a strong predictor for colon cancer and esophageal squamous
carcinoma.

Figure 10.6 Funnel plot of ALDH1 genes expression and disease-free survival in HNSCC

This funnel plot indicated no obvious publication bias for disease-free survival of head and neck
squamous carcinoma cancer with ALDH1 genes expression.

Figure 10.7 Funnel plot of ALDH1 genes expression and overall survival in non-small cell lung cancer
Figure 10.8 Funnel plot of ALDH1 genes expression and disease-free survival in non-small cell lung cancer

Figure 10.7 suggested minor evidence for publication bias in checking association of ALDH1 and
overall survival in non-small cell lung cancer. There was outlier study that made the funnel asymmetric.
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Figure 10.8 suggested no obvious evidence for publication bias in association of ALDH1 and diseasefree survival in non-small cell lung cancer. The funnel was in a symmetric shape and studies scattered
around the pooled Hazard Ratio. But within each subgroup, the studies were not distributed
symmetrically.

Figure 10.9 Funnel plot of ALDH1 genes expression and overall survival in ovarian cancer
Figure 10.10 Funnel plot of ALDH1 genes expression and disease-free survival in rectal cancer

Funnel plots 10.9 and 10.10 didn’t show significant publication bias, which were strong evidence of
ALDH1 being a prognosis predictor for patients with ovarian cancer and rectal cancer.

Figure 10.11 Funnel plot of ALDH1A2 and prognosis in cancer patients
Figure 10.12 Funnel plot of ALDH1A3 and prognosis in cancer patients
Figure 10.13 Funnel plot of ALDH1L1 and prognosis in cancer patients

The three funnel plots provided information as whether more investigation was required to examine the
prognosis effect of ALDH1A2, ALDH1A3, and ALDH1L1 subfamilies.
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Discussion
In recent studies, a particular sub-group of tumor cells are believed to play a critical role in cancer,
which is called cancer stem cells(CSCs) or tumor initiating cells(TICs). The most important
characteristics of CSCs are enhanced tumorigenicity and the capacity for self renewal and self
differentiation. The ALDH activity has been identified and can separate CSCs from a series of cancer
types [23, 173]. The ALDH isozymes actively participate in various physiological responses including
drug resistance and RA formation, also ALDH isozymes can protect stem cells from toxic endogenous
and exogenous aldehydes. Hence ALDHs can be a potential stem cell marker, or cancer stem cell
predictor [174]. Among the nineteen ALDH isoenzymes, ALDH1A1 was extensively considered to
interact with cancer stem cells including breast cancer and non-small cell lung cancer. Studies on murine
hematopoietic stem cells, murine progenitor pancreatic cells, and breast cancer stem cells demonstrated
that ALDH1A3 expression may result in aldefluor positivity, which exerted influence in regulation CSCs
[63]. Previous researches have indicated the potential of ALDHs to predict cancer patients’ outcome
because of its role in CSCs.

Unlike Relative Risk or Odds Ratio, Hazard Ratio is the time-to-event analysis instead of event analysis.
In order to study the prognosis effect of ALDH in cancer patients, estimation is conducted to evaluate
the proportion of cancer patient group who would survive in a given length of time under the same
ALDH status from a set of observed survival time interval. And Kaplan-Meier curve is constructed in
the already published papers to display the survival functions. The Cox model is used to simultaneously
explore the effects of different risk factors related to cancer patients’ survival, or different combinations
of covariates to cancer patients death [175]. As to the clinical outcomes of overall survival or diseasefree survival, the Cox Regression Model is based on the assumption that the predictor variable are
constant over time and additive in log scale. The Cox model can allow isolation the ALDH expression
status from other contributable variables to survival outcome, by adjusting other covariates effects.

Meta-analysis can provide a more accurate estimation of researched effect, because meta gives weight
to each studies based on the sample size and include individual researches into meta-analysis. The
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reason why a meta-analysis is conducted on ALDH prognosis effect on cancer patient is that it can
address certain practical difficulties that may beset anyone trying to make sense of prediction of ALDH
prognosis influence. The validity of this meta-analysis study depends on the quality of the systematic
review on the survival analysis considering ALDH expression in cancer patients. This meta-analysis
study aims to assess all relevant studies on ALDH and cancer patients’ survival analysis, presents a
decent summary of existing researches, looks for the presence of heterogeneity and unbiased synthesis
among these published studies, and explore the robustness of the main findings using sensitivity analysis.
To overcome bias, a rigorous systematic review is conducted to quantitatively evaluate survival
outcomes and ALDH1 expression status. A well-executed meta-analysis requires a complete unbiased
collection of all the original studies of acceptable quality that examine prognosis of ALDH1 on cancer
patients. Sensitivity analysis will help explore the effect of excluding various categories of studies and
how consistent the results are among studies[176].

This meta-analysis found ALDH1 genes expression is association with poor overall survival of breast
cancer (HR: 1.83) and disease-free survival of breast cancer (HR: 1.61). The significant association
provided evidence of ALDH1 families as prognosis predictor for breast cancer patients. The adjusted
Hazard Ratio provided an even stronger association for ALDH1 genes prognosis. This conclusion is
consistent with most of published studies, but some studies did conclude different way. The
inconsistency with conclusion from Liu [135] might be attributed to specific breast cancer, triplenegative breast cancer, and also because of the experiment design of gene expression from stromal cells
or cancer cells, or the analysis with different cohort effect sizes.

This meta-analysis also found ALDH1 genes expression is associated with poor overall survival in colon
cancer (HR: 2.13). This association is not significant, however the adjusted overall survival is
significantly associated with ALDH1 genes expression status. The conclusion that ALDH1 genes are
poor prognosis of colon cancer is consistent with previous researches. For patients with esophageal
squamous carcinoma, this meta-analysis discovered the insignificant association of ALDH1 genes with
poor overall survival (HR: 1.22) and with disease-free survival (HR: 1.84). The researches included
38

proposed controversial prognosis effect of ALDH1. The controversy of conclusion may be related to
the different treatment received by esophageal squamous carcinoma [106] or age group [105]. The
expression of ALDH1 in esophageal squamous carcinoma patients required further investigation in
order to draw meaningful conclusion and check the prognosis effect. A most unique and important
finding in this meta-analysis study is that ALDH1 is a significant poor prognosis of disease-free survival
in rectal cancer patients (HR: 2.57). The result is consistent with each of the four original researches
found. Researches can be conducted simultaneously for colon cancer and rectal cancer, which is
believed to originate from normal stem cells.

Another important finding of this study is the association of ALDH1 genes expression with poor
prognosis in non-small cell lung cancer patients, both for overall survival (HR: 1.94) and disease-free
survival (HR: 1.32). And the adjusted HR indicated a stronger association for poor prognosis. Previous
studies that concluded in different prognosis effect may not use multivariate analysis by Cox Regression
Model as reported in You [38]. The opposite conclusion of good prognosis of disease-free survival may
also be due to AQUA score-defined threshold of detecting ALDH1 genes expression [157]. Because of
the limited researches found on ALDH1A2, ALDH1A3, ALDH1B1, and ALDH1L1, this meta-analysis
for non-small cell lung cancer prognosis didn’t include results from such ALDH1 genes. According to
You [38], high expression of ALDH1A2 and ALDH1B1 was significantly associated with poor overall
survival in NSCLC patients. Thus ALDH1A2 and ALDH1B1 might be good potential drug targets and
overall survival predictor for NSCLC patients.

This meta-analysis also concluded that there’s association of ALDH1 genes especially ALDH1A1
expression with poor prognosis of overall survival in ovarian cancer patients (HR: 1.48). The significant
poor prognosis effect is consistent with most of what original researches found [117, 120]. But some
research concluded different way as favorable prognosis of ALDH1 for ovarian cancer [124]. In Chang’s
study [124], high levels of ALDH1 expression was associated with endometrioid adenocarcinoma, early
disease stage, complete response to chemotherapy and favorable survival. The cut-off point in determine
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high and low ALDH1 expression was 20%. The prognosis markers for identifying one type cancer cells
may not always be useful for predicting other types of cancer cells [177-179].

The forest plots and funnel plots were mapped by Review Manager 5.3. To conduct a meta-analysis for
Hazard Ratio in RevMan, logHR and se(logHR) are needed to be transformed from reported Hazard
Ratio. Papers that either reported HR with 95%CI or HR with p-value fit the transformation calculation
and the calculation was based on Hazard Ratio Meta-analysis Spreadsheet. This spreadsheet was
developed by Hans Messersmith using the methods in Parmar [71] in Statistics in Medicine. Unlike
other softwares including R, SAS, SPSS, RevMan didn’t require the 95%CI for HR reported in the
original researches in order to meet the inclusion criteria. Because some papers may not report 95%CI
and only reported p-value for HR if the prognosis association was not significant, this transformation
provided method to be incorporated into meta-analysis. The method was also proposed by Parmar [71].
STATA and RevMan are useful in processing subgroup meta-analysis, while other softwares were more
strict in subgroup meta. Especially RevMan is easier for sensitivity analysis to sequentially exclude
each individual research from meta-analysis and repeat the whole process to see if pooled Hazard Ratio
will be significantly altered.

The limitations of this meta-analysis study concerns with four parts. In the first place, even if the data
extraction method from Kaplan-Meier curve can include more validated researches, the HR calculated
this way is unadjusted HR. Other published papers which already include the HR and 95%CI mainly
use Cox regression model and calculate adjusted hazard ratio. This study didn’t separate adjusted HR
and unadjusted HR into different categories. Hence the interpretation of overall HR cannot be arbitrarily
concluded as controlling other covariates. The influence of covariates in survival in cancer patients
remain unclear, and this can reduce the validation of overall results. There might be a situation when
some covariates contribute more to prognosis than ALDH1 genes expression status and not properly
controlling the covariates can affect HR in both directions. Another problem with this data extraction
method is the calculation of 95%CI is dependent on sample size. The studies with small sample size
tend to have a broader 95%CI range, even if the original paper provided a significant p-value based on
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either log-rank test or Cox regression model. There’s a tradeoff in using this data extraction method to
include validated outcomes, and it can reduce the selection bias from inclusion process while not
guarantee the uniform data analysis. In addition, the cut-off points for ALDH1 genes expression status
is not uniform, with some studies deciding positive and negative status based on their specific
immunology results. This meta-analysis didn’t transform such criteria and standardize it. The choice of
cut-off points will also exert influence the final result, especially when it’s not merely expression versus
non-expression. A higher cut-off point will weaken the calculation of HR and draw it to the direction
towards 1.This meta-analysis study didn’t cover all the cancer types found from database. Further
original researches should be conducted on the prognosis effect and the less-studied cancer types. Next
when interpreting the hazard ratio for a survival analysis, it’s better to take into consideration of time
such as median survival time under scrutiny, comparison of two groups at the time point that half of
patients experienced the event. This meta-analysis didn’t include the information about time in each
study. Finally, the Hazard Ratio meta-analysis using Review Manager needs the log transformation for
Hazard Ratio, 95%CI, or p-value. As such calculation is taken into consideration of sample size, some
studies may include more than one cohort for prognosis analysis. Thus the calculation by Review
Manager may differentiate the original HR and 95%CI provided by the original papers.

Conclusions
ALDH1 genes expression is associated with poor overall survival of breast cancer (HR: 1.83), poor
disease-free survival of breast cancer (HR: 1.61), poor overall survival of colon cancer (HR: 2.13), poor
overall survival of non-small cell lung cancer (HR: 1.94), poor overall survival of ovarian cancer (HR:
1.48) and poor disease-free survival of rectal cancer (HR: 2.57). This study also found ALDH1 genes
expression is not associated with disease-free survival of non-small cell lung cancer, overall survival
and disease-free survival of esophageal squamous carcinoma, as well as disease-free survival of Head
and Neck Squamous Carcinoma Cancer. Expression of ALDH1 genes predicts poor prognosis for breast
cancer, colon cancer, non-small cell lung cancer, ovarian cancer and rectal cancer.
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Competencies
Describe the mechanisms of toxicity of biological, chemical, and physical stressors, including
absorption, distribution, metabolic transformation, elimination, and genetic susceptibility.
This thesis describes aldehyde dehydrogenases family and its use as prognosis factors
for certain human cancer types. Unlike mechanistic studies on ALDH1 genes, this study
attempts to discover clinical utility of ALDH1 genes for cancer patients.
Review, critique, and evaluate environmental epidemiology research articles.
The meta-analysis is a comprehensive review of already published papers on ALDH1
genes families and human cancers.
Synthesize information from a variety of environmental health and related studies
The meta-analysis analyzed and organized data from each related papers and made a
comprehensive summary to assess all possible original researches concerning survival
analysis of ALDH1 genes among cancer patients.
Use epidemiological, exposure assessment, toxicological and statistical techniques in assessing
the risks associated with environmental hazards in the working, residential, and community
environment.
The statistical analysis helps in discovering the ALDH1A1, ALDH1A2, ALDH1A3,
ALDH1B1, ALDH1L1 level and activity in association with breast cancer, lung cancer
and esophageal cancer or other cancer types among humans. It shed light on how
enzymes may work as prognosis biomarkers for these cancers.
Explain the interrelationships among a multitude of factors that can influence a public health
problem.
The study aims to find out the correlation or association between ALDH1 genes
expression and prognosis for cancer patients. It is more important to improve the life
quality of cancer patients, including preventing the recurrence of cancer for humans.
By identifying the prognosis effect, this study can disclose the clinical potential of
ALDH1 families as marker for prognosis prediction. This can provide recommendation
for personalized treatment for cancer patients.
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Innovation of This Meta-Analysis
Previous Systematic Review and Meta-Analysis for prognosis effect of ALDH1 genes on cancer
studies didn’t provide enough information about categorical difference in six ALDH1 genes.
The majority of papers put the six ALDH1 genes together without specifying the isozymes. This
meta-analysis specified ALDH1 isozymes into six subtypes as ALDH1, ALDH1A1, ALDH1A2,
ALDH1A3, ALDH1B1, ALDH1L1, ALDH1L2 (no prognosis research) and then combine
isozymes together and carry out the analysis as ALDH1 family. It’s a more comprehensive
systematic review compared to targeting at only one isozyme and its prognosis effect.
The HR calculation based on Kaplan-Meier curve data extraction provides a more validated
result for meta-analysis study. Excluding the survival analysis paper that didn’t calculate HR
can bring in bias for the entire study results. Including the unadjusted calculated HR can give
weight to such studies that meet inclusion criteria for this meta-analysis studies. This estimation
method extends validated study sample for prognosis effect of ALDH1 genes.
This study shed enlightening light on exploration and examination of whether ALDH1 can be a
clinical biomarker in predicting prognosis as well as metastasis. Its clinical significance for
survival prediction caters to the trend of personalized medicine and arising genetic sequencing
skill utility. The conclusion of the study enriches the clinical utility of ALDH1 genes, and can
work as new mechanism for drug treatment and cancer progression pathway. This meta-analysis
also provides basis for prognosis effect of other ALDH genes like ALDH2, and the cancer types
cover some of the most common one. By categorizing cancer type, the prognosis prediction has
even more clinical significance in personalized treatment for cancer patients.
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